1. Home
  2. SST vs VRCA Comparison

SST vs VRCA Comparison

Compare SST & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo System1 Inc.

SST

System1 Inc.

HOLD

Current Price

$4.65

Market Cap

67.7M

ML Signal

HOLD

Logo Verrica Pharmaceuticals Inc.

VRCA

Verrica Pharmaceuticals Inc.

HOLD

Current Price

$8.21

Market Cap

32.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SST
VRCA
Founded
2013
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.7M
32.7M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
SST
VRCA
Price
$4.65
$8.21
Analyst Decision
Strong Buy
Buy
Analyst Count
1
3
Target Price
$10.00
$17.00
AVG Volume (30 Days)
27.1K
364.4K
Earning Date
11-05-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$289,784,000.00
$30,829,000.00
Revenue This Year
N/A
$373.20
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
234.73
52 Week Low
$2.90
$3.28
52 Week High
$15.00
$9.82

Technical Indicators

Market Signals
Indicator
SST
VRCA
Relative Strength Index (RSI) 51.52 61.02
Support Level $4.36 $7.75
Resistance Level $4.77 $8.68
Average True Range (ATR) 0.35 0.86
MACD 0.09 -0.12
Stochastic Oscillator 43.16 65.99

Price Performance

Historical Comparison
SST
VRCA

About SST System1 Inc.

System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

Share on Social Networks: